

## Awards...



### PTC FOUNDER RECEIVES SOL J. BARER AWARD

PTC Therapeutics' Founder and CEO Stuart Peltz, Ph.D., has been awarded the 2014 Dr. Sol J. Barer Award for Vision, Innovation, and Leadership. Named for Sol J. Barer, Ph.D., founder and former chairman and CEO of Celgene, the award recognizes research and business leaders who have made significant



contributions to the growth and prosperity of the biosciences industry in New Jersey and throughout the world.

Dr. Peltz was honored in 2009 as a PharmaVOICE 100 for his scientific creativity, business pragmatism, and operational ingenuity.

## PharmaVOICE.com

### WEB SEMINAR

#### Digital Signatures for Corporate Governance & Compliant Collaboration

April 9, 2014, 1pm ET

Sponsored by: CoSign by ARX

### WHITE PAPERS

#### Cutting Costs, Saving Time: Improving Life Sciences Operations with Digital Signatures

Provided by: CoSign by ARX

#### Case Study: Tracking and Evaluating Marketing and Digital Media Initiatives by Measuring Social Media Efficacy

Provided by: Genpact

#### Case Study: Tracking Brand Sentiments Through Social Media Analysis: Putting a Leading OTC Brand in Control

Provided by: Genpact

#### Five Steps to Analytical Maturity: A Guide for Pharma Commercial Operations

Provided by: SAS

#### Anticipating Success: Meeting the Inherent Development Challenges of Complex Injectable Drug Substances

Provided by: Vetter Pharma International

## INDUSTRY at Large ▼

### AbbVie Announces Art Gallery On CHRONIC INFLAMMATORY DISEASE

AbbVie has launched Perspectives — Art, Inflammation and Me, an initiative designed to add a different dimension to the current understanding of immune-mediated inflammatory diseases and their impact on patients and society.

More than **200** artistic expressions provide new perspectives into some of the often underestimated burdens associated with these conditions. The initiative involves more than **200** artists from more than **40** countries around the world. Perspectives will visit various art galleries and medical conferences throughout the world.

"The stories and artworks in Perspectives contribute to the current understanding of these diseases and their impact on patients and society



Artist Barbara Miller's depiction represents a patient with Crohn's disease who, much like a game, has personal wins, losses, and draws when dealing with a chronic illness.

from a very personal and emotional point of view," says Isidro Villanueva, M.D., Ph.D., group therapeutic area lead, medical affairs, immunology, at AbbVie.

### ACA Lowers PRESCRIPTION COSTS

There has been slower growth in health spending since the implementation of the Affordable Care Act, according to a recent report from the Centers for Medicare and Medicaid Services (CMS). This is consistent with data showing savings from generic medicines reaching **\$217** billion in **2012** and **\$1.2** trillion over the most recent decade, according to the **2013** Report on Generic Drug Savings in the U.S., the fifth annual report compiled by IMS Health on behalf of the Generic Pharmaceutical Association (GPhA).

Overall national health expenditures grew at an annual rate of **3.7%** in **2012**, marking the fourth consecutive year of low growth, the CMS Office of the Actuary reports. Health spending as a share of gross domestic product fell slightly from **17.3%** in **2011** to **17.2%** in **2012**.

### Life-Sciences VENTURE CAPITAL DECLINES

Venture capital funding for the life-sciences sector declined by **1%** in dollars invested and **3%** in number of deals compared with **2012**, according to a PwC US report, which includes data from the MoneyTree Report from PwC and the National Venture Capital Association based on data provided by Thomson Reuters. VCs invested **\$6.6** billion into **778** life-sciences deals in **2013**, compared with **\$6.7** billion in **800** deals in **2012**.

Biotech companies raised **\$4.5** billion in **470** deals during **2013**, placing it as the second-largest investment sector behind software. Investments in biotechnology for all of **2013** increased by **8%** in value, while volume declined by **2%**. Investments in biotechnology increased **43%** in dollars and

**10%** in deals with **\$1.3** billion flowing into **134** deals during the fourth quarter of **2013**.

"With the strong exit markets for biotech in **2013**, **2014** is set up for renewed interest in life sciences," says Greg Vlahos, life-sciences partner, PwC. "First-time funding saw a strong finish to the year. The enduring interest in early-stage opportunities will continue to drive investments in the sector."



Greg Vlahos

## Innovation Corner...

### GSK Launches 2014 DISCOVERY FAST TRACK CHALLENGE

GSK is inviting academic scientists to enter their most innovative drug research proposals into its 2014 Discovery Fast Track Challenge, a program designed to accelerate the translation of early-stage research into new medicines.

Building on the success of its first program in 2013, which ran in the United States and Canada, GSK is implementing the challenge for a second year and expanding it to include Europe.

Scientists whose entries are selected will collaborate with GSK's Discovery Partnerships with Academia (DPAC) team to test their hypotheses on potential disease pathways or targets against GSK's library of compounds.

"Through this challenge we're paving the way for innovative new collaborations between academic scientists and investigators in GSK's DPAC team," says Pearl Huang, global head of DPAC.s

# MediScripts® Secure Rx™ Prescription Pads

Deliver brand messages to targeted physicians at the point of prescription decision.



Secure Rx™



mediscripts®

201-727-1555

[www.mediscriptspartners.com](http://www.mediscriptspartners.com)